Navigation Links
Sunitinib a Promising Agent for Treatment of Renal Cell Cancer

Sunitinib has been found to be an effective agent for treating metastatic renal cell cancer, a disease for which no effective treatment options are available so far//.

There is an urgent need for more active agents for the treatment of metastatic (spread of cancer from point of origin to another part of the body) renal cell carcinoma (RCC). The 5-year survival rate for metastatic RCC is estimated to be less than 10 percent, according to background information in the article. RCC is highly resistant to chemotherapy, and only a limited subset of patients (20 percent or less) benefit from cytokine (proteins from the immune system) therapy (high-dose interleukin-2 [IL-2] and/or interferon-alfa). Overall median survival following progression after cytokine therapy is approximately 10 to 13 months, and no effective treatment is available for patients whose disease progresses after an initial response, or who do not respond to cytokine therapy.

A better understanding of the genetic abnormalities associated with clear-cell RCC has helped identify new targets for therapy, and subsequently the development of a new therapy, the oral medication sunitinib, which had positive results in an initial study.

Robert J. Motzer, M.D., of Memorial Sloan-Kettering Cancer Center, New York, and colleagues conducted a multicenter phase 2 trial to confirm the antitumor efficacy of sunitinib in 106 patients with metastatic clear-cell RCC whose disease was refractory (unresponsive) to 1 prior cytokine therapy.

Patients were enrolled between February and November 2004, with follow-up continuing until disease progression, unacceptable toxicity, or withdrawal of consent. Patients received repeated 6-week cycles of sunitinib, 50 mg per day given orally for 4 consecutive weeks followed by 2 weeks off per treatment cycle.

“The results of this trial confirm that sunitinib given once daily according to a 4 weeks on/2 weeks off schedule has sub stantial antitumor effects against metastatic clear-cell RCC. Of the 105 evaluable patients, 36 patients achieved partial response (34 percent), and a median progression-free survival of 8.3 months as evaluated by the independent third-party core imaging laboratory (resulting in a value considerably longer than expected in this clinical setting),” the authors write.

The most common adverse events experienced by patients were fatigue 30 (28 percent) and diarrhea 21 (20 percent).

(Source: Newswise)
'"/>




Related medicine news :

1. Promising Treatment for Diabetes
2. Life after Bypass not so Promising for Women.
3. Promising cure for West Nile Virus
4. Deadly Diarrhoea Vaccine – Trail Results Promising
5. Novartis MS Drug Shows Promising Results
6. Promising Care Model For Bipolar Disorder
7. A Promising New Vaccination Strategy for Late-Stage Melanoma
8. Promising Brain Tumor Treatment In The Offing
9. Sea Creatures Toxin Could Lead to Promising Cancer Treatment
10. Vaccine Promising Against Hepatitis E
11. Groups Join Forces to Fund Promising Lung Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/16/2018)... Wash. (PRWEB) , ... October 16, 2018 , ... ... Pizzorno was the recipient of the Academy of Integrative Health and Medicine’s (AIHM) ... dedicated to natural medicine. , Dr. Pizzorno was selected as AIHM’s recipient ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... Bethesda, MD, http://www.fdanews.com/fdainspectionssummit , The 13th Annual FDA Inspections Summit starts ... that it sometimes feels difficult to keep up. The FDA is focused on ...
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... The months of training are over. The ... their bodies will probably feel like they were put through the wringer after the big ... sports injuries team at Medicine in Motion on how to treat the body and mind ...
(Date:10/13/2018)... ... October 12, 2018 , ... At HEI Health, we believe tomorrow’s healthcare ... attending this year’s National Healthcare CXO Fall Summit by Marcus Evans. HEI will be ... and Patient Experience challenges with leading healthcare providers. , Marcus Evans National Healthcare ...
(Date:10/13/2018)... , ... October 13, 2018 , ... This World Food ... world that it IS possible to end hunger by 2030 by breaking a GUINNESS ... from several of their 28 U.S. based locations and five international locations together to ...
Breaking Medicine News(10 mins):
(Date:10/16/2018)... Tenn. (PRWEB) , ... October 16, 2018 , ... ... acquisition of Applied Logic, the St. Louis based surgical tracking software company. Censis ... empowering their customers and employees to make a difference using their strong portfolio ...
(Date:10/16/2018)... ... October 16, 2018 , ... With suicide as the ... problem (1), the American Psychiatric Nurses Association (APNA) has released a new training to ... safe. Though deaths by suicide in hospital settings are preventable, a recent survey of ...
(Date:10/13/2018)... ... October 12, 2018 , ... ... public that Pensacola is open and has hotel availability for anyone in need, ... Michael has passed through Northwest Florida. In the aftermath, Pensacola is open and ...
Breaking Medicine Technology: